Company

Onxeo SA

Headquarters: Paris, France

Employees: 29

CEO: Mr. Julien Miara

Euronext: ALONX +4.35%

Market Cap

€30.2 Million

EUR as of July 1, 2023

US$32.9 Million

Market Cap History

Onxeo SA market capitalization over time

Evolution of Onxeo SA market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Onxeo SA

Detailed Description

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Onxeo SA has the following listings and related stock indices.


Stock: Euronext: ALONX wb_incandescent

Stock: FSX: C4X wb_incandescent

Stock: OMXC: ONXEO wb_incandescent

Details

Headquarters:

49, boulevard du GEnEral Martial Valin

Paris, 75015

France

Phone: 33 1 45 58 76 00

Fax: 33 1 45 58 08 81